Skip to main content

Advertisement

SpringerLink
Log in

Clinical Significance of Loss of Fhl1 Expression in Human Gastric Cancer

  • Laboratory Research
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Human four-and-a-half LIM domains 1 (Fhl1) gene has been reported to achieve cancer suppressive effects. The purpose of this study is to clarify clinical significance of Fhl1 expression in gastric cancer.

Methods

Fhl1 mRNA expression was quantified by real-time reverse transcription (RT)-polymerase chain reaction (PCR) using paired tumor and normal clinical samples from a total of 110 gastric cancer patients. Fhl1 protein expression was investigated by immunohistochemistry. The relationship between Fhl1 mRNA expression and clinicopathological factors was statistically analyzed.

Results

Fhl1 mRNA expression in tumor tissue was significantly downregulated compared with that in normal mucosa (P < 0.0001). Fhl1 protein expression was also diminished in cancer cells by immunohistochemistry. Kaplan–Meier survival curves demonstrated that the patients with low Fhl1 expression tumor showed significantly shorter survival (P < 0.05) than those with high Fhl1 expression tumor. Furthermore, the tumors with low Fhl1 expression showed deeper invasion into the serosal layer (P < 0.05) or more frequent distant metastasis (P < 0.01).

Conclusion

Fhl1 gene was underexpressed in clinical gastric cancer. Loss of Fhl1 expression would be a novel biomarker to determine biological aggressiveness of gastric cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Roder DM. The epidemiology of gastric cancer. Gastric Cancer 2002; 5:5–11.

    Article  PubMed  Google Scholar 

  2. Alberts SR, Cervantes A, van de Velde CJ. Gastric cancer: epidemiology, pathology and treatment. Ann Oncol 2003; 14:31–6.

    Google Scholar 

  3. Jemal A, Tiwari RC, Murray T, et al. Cancer Statistics, 2004. CA Cancer J Clin 2004; 54:8–29.

    Article  PubMed  Google Scholar 

  4. Mori M, Mimori K, Yoshikawa Y, et al. Analysis of the gene-expression profile regarding the progression of human gastric carcinoma. Surgery 2002; 131:S39–47.

    Article  PubMed  Google Scholar 

  5. Hashimoto Y, Shimada Y, Kawamura J, et al. The prognostic relevance of Fascin expression in human gastric carcinoma. Oncology 2004; 67:262–70.

    Article  PubMed  CAS  Google Scholar 

  6. Partin AW, Schoeniger JS, Mohler JL, et al. Fourier analysis of cell motility: Correlation of motility with metastatic potential. Proc Natl Acad Sci USA 1989; 86:1254–8.

    Article  PubMed  CAS  Google Scholar 

  7. Liotta LA, Kohn EC. The microenvironment of the tumor-host interface. Nature 2001; 411:375–9.

    Article  PubMed  CAS  Google Scholar 

  8. Ramaswamy S, Ross KN, Lander ES, et al. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003; 33:49–54.

    Article  PubMed  CAS  Google Scholar 

  9. Oku N, Sasabe E, Ueta E, et al. Tight junction protein claudin-1 enhances the invasive activity of oral squamous cell carcinoma cells by promoting cleavage of laminin-5 γ2 chain via matrix metalloproteinase (MMP)-2 and membrane-type MMP-1. Cancer Res 2006; 66:5251–7.

    Article  PubMed  CAS  Google Scholar 

  10. Johannessen M, Møller S, Hansen T, et al. The multifunctional roles of the four-and-a-half-LIM only protein FHL2. Cell Mol Life Sci 2006; 63:268–84.

    Article  PubMed  CAS  Google Scholar 

  11. Morgan MJ, Madgwick AJ, Charleston B, et al. The developmental regulation of a novel muscle LIM-protein. Biochem Biophys Res Commun 1995; 212:840–6.

    Article  PubMed  CAS  Google Scholar 

  12. Brown S, McGrath MJ, Ooms LM, et al. Characterization of two isoforms of the skeletal muscle LIM protein 1, SLIM1. J Biol Chem 1999; 274:27083–9.

    Article  PubMed  CAS  Google Scholar 

  13. Shen Y, Jia Z, Nagele RG, et al. Src uses Cas to suppress Fhl1 in order to promote nonanchored growth and migration of tumor cells. Cancer Res 2006; 66:1543–52.

    Article  PubMed  CAS  Google Scholar 

  14. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 2001; 98:13790–5.

    Article  PubMed  CAS  Google Scholar 

  15. Finley DJ, Arora N, Zhu B, et al. Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules. J Clin Endocrinol Metab 2004; 89:3214–23.

    Article  PubMed  CAS  Google Scholar 

  16. Fryknäs M, Wickenberg-Bolin U, Göransson H, et al. Molecular markers for discrimination of benign and malignant follicular thyroid tumors. Tumor Biol 2006; 27:211–20.

    Article  CAS  Google Scholar 

  17. Japanese Gastric Cancer Association: Japanese classification of gastric cancer, 2nd English Edition. Gastric Cancer 1998; 1:10–24

  18. Jass JR, Sobin LH, Watanabe H. The World Health Organization’s histologic classification of gastrointestinal tumors. A commentary on the second edition. Cancer 1990; 66:2162–7.

    Article  PubMed  CAS  Google Scholar 

  19. Lauren P. The two histological main types of gastric carcinoma. Diffuse and so-called intestinal type carcinoma. An attempt at histoclinical classification. Acta Pathol Microbio Scand 1965; 64:31–49.

    CAS  Google Scholar 

  20. Ohmachi T, Tanaka F, Mimori K, et al. Clinical significance of TROP2 expression in colorectal cancer. Clin Cancer Res 2006; 12:3057–63.

    Article  PubMed  CAS  Google Scholar 

  21. Ogawa K, Utsunomiya T, Mimori K, et al. Clinical significance of human kallikrein gene 6 messenger RNA expression in colorectal cancer. Clin Cancer Res 2005; 11:2889–93.

    Article  PubMed  CAS  Google Scholar 

  22. Sasaki A, Iwashita Y, Shibata K, et al. Improved long-term survival after liver resection for hepatocellular carcinoma in the modern era: Retrospective study from HCV-endemic areas. World J Surg 2006; 30:1567–78.

    Article  PubMed  Google Scholar 

  23. Yang S, Shin J, Park KH, et al. Molecular basis of the differences between normal and tumor tissue of gastric cancer. Biochimica et Biophysica Acta 2007; 1772:1033–40.

    PubMed  CAS  Google Scholar 

  24. Brábek J, Constancio SS, Shin NY, et al. CAS promotes invasiveness of Src-transformed cells. Oncogene 2004; 23:7406–15.

    Article  PubMed  CAS  Google Scholar 

  25. Shin NY, Dise RS, Schneider-Mergener J, et al. Subsets of the major tyrosine phosphorylation sites in Crk-associated substrate (CAS) are sufficient to promote cell migration. J Biol Chem 2004; 279:38331–7.

    Article  PubMed  CAS  Google Scholar 

  26. Goldberg GS, Alexander DB, Pellicena P, et al. Src phosphorylates Cas on tyrosine 253 to promote migration of transformed cells. J Biol Chem 2003; 278:46533–40.

    Article  PubMed  CAS  Google Scholar 

  27. Mayer B, Johnson JP, Leitl F, et al. E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration. Cancer Res 1993; 53:1690–5.

    PubMed  CAS  Google Scholar 

  28. Wang J, Yang Y, Xia HHX, et al. Suppression of FHL2 expression induces cell differentiation and inhibits gastric and colon carcinogenesis. Gastroenterology 2007; 132:1066–76.

    Article  PubMed  CAS  Google Scholar 

  29. Ng EKO, Lee SMY, Li H-Y, et al. Characterization of tissue-specific LIM domain protein (FHL1C) which is an alternatively spliced isoform of a human LIM-only protein (FHL1). J Cell Biochem 2001; 82:1–10.

    Article  PubMed  CAS  Google Scholar 

  30. Grossi M, Hiou-Feige A, Di Vignano AT, et al. Negative control of keratinocyte differentiation by Rho/CRIK signaling coupled with up-regulation of KyoT1/2 (FHL1) expression. Proc Natl Acad Sci USA 2005; 102:11313–8.

    Article  PubMed  CAS  Google Scholar 

  31. LaTulippe E, Satagopan J, Smith A, et al. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 2002; 62:4499–506.

    PubMed  CAS  Google Scholar 

  32. Dai N, Bao Q, Lu A, et al. Protein of Osteopontin in tumor tissues is an independent prognostic indicator in gastric cancer. Oncology 2007; 72:89–96.

    Article  PubMed  CAS  Google Scholar 

  33. Sakamoto Y, Sano T, Shimada K, et al. Favorable indications for hepatectomy in patients with liver metastasis from gastric cancer. J Surg Oncol 2007; 95:534–9.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We thank T. Shimooka, K. Ogata, M. Oda, N. Kasagi, and Y. Nakagawa for their excellent technical assistance. This work was supported in part by the following grants and foundations: CREST, Japan Science and Technology Agency (JST); Japan Society for the Promotion of Science (JSPS), Grant-in-Aid for Scientific Research, grant numbers 17109013, 17591411, 17591413, 18390367, 18590333, 18659384, and 18790964; The Ministry of Education, Culture, Sports, Science and Technology (MEXT) Grant-in-Aid for Scientific Research on Priority Area, grant number 18015039.

Author information

Authors and Affiliations

  1. Department of Surgery and Molecular Oncology, Medical Institute of Bioregulation, Kyushu University, 4546 Tsurumihara, Beppu, 874-0838, Japan

    Katsuya Sakashita MD, Koshi Mimori MD, PhD, Fumiaki Tanaka MD, PhD, Yukio Kamohara MD, PhD, Hiroshi Inoue MD, PhD & Masaki Mori MD, PhD

  2. Department of Surgical Oncology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan

    Katsuya Sakashita MD, Tetsuji Sawada MD, PhD & Kosei Hirakawa MD, PhD

Authors
  1. Katsuya Sakashita MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Koshi Mimori MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fumiaki Tanaka MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yukio Kamohara MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hiroshi Inoue MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tetsuji Sawada MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kosei Hirakawa MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Masaki Mori MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masaki Mori MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sakashita, K., Mimori, K., Tanaka, F. et al. Clinical Significance of Loss of Fhl1 Expression in Human Gastric Cancer. Ann Surg Oncol 15, 2293–2300 (2008). https://doi.org/10.1245/s10434-008-9904-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-008-9904-3

Keywords

Search

Navigation